Innovative Therapeutics Angiocrine Bioscience specializes in engineered endothelial cell therapies that target serious hemato-oncologic and immunologic conditions, presenting opportunities to collaborate or supply related biomanufacturing services to support their clinical pipeline.

Clinical Progress With a focus on Phase 3 clinical trials and a recent presentation at the American Society of Hematology, the company is advancing toward potential commercialization, indicating a need for advanced diagnostic, logistics, and regulatory support services.

Funding & Growth Having secured $6 million in grants and holding revenues estimated between $10M and $25M, Angiocrine is positioned for expansion in its R&D activities, offering opportunities for partnership in biotech tools, late-stage clinical services, and capital investment.

Research Focus The company's emphasis on tissue regeneration and repairing damaged organs opens potential sales avenues in regenerative medicine products, biomaterials, and stem cell infrastructure tailored to cellular therapies.

Scientific Collaboration Given its proprietary platform and focus on engineered cell therapies, there is a significant opportunity for sales of specialized bioprocessing equipment, cell manufacturing technologies, and contract research services that can enhance their R&D capabilities.